Ultimovacs ASA

As of December 31, 2024, Ultimovacs ASA has 34.41M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Ultimovacs ASA maintains a current ratio of 3.62, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.53, indicating elevated leverage, while an interest coverage ratio of -109.29 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -86.50, reflecting losses generated across the asset base.

These figures cover the twelve months ended December 31, 2024. Free cash flow yield is negative at -203.81: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 2.76, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ultimovacs ASA shareholders.

As of December 31, 2024, Ultimovacs ASA has an Altman Z-Score of -14.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.